One previous study reported that 40% of patients with CKD-5D and hyporesponsiveness to ESAs achieved or remained within the Hb concentration target range (10.5–11.0 g/dL) after 12 weeks of treatment with daprodustat (23). The gene discussed is GSTM1; the disease is chronic kidney disease.